Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
AI-summarised brief · reviewed before publication
Enveda, a biotech startup that applies artificial intelligence to identify drugs from natural sources, secured $311 million in a Series E round, elevating its valuation to $2 billion. The funding, led by Catalio Capital Management with participation from Iconiq and other investors, doubles the company’s valuation from a year earlier. Founded in 2019 by Viswa Colluru, Enveda focuses on accelerating discovery of plant- and microbe-derived therapeutics. It currently advances several candidates into human trials, including treatments for severe skin conditions and post‑GLP‑1 weight‑loss maintenance.
💡 Why It Matters
- · The infusion underscores growing investor confidence in AI‑driven natural product discovery, positioning Enveda as a key player in expanding the pipeline of biologically sourced therapeutics.